SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

HUNKAPILLER MICHAEL W

(Last)

(First)

(Middle)

APPLERA CORP - APPLIED BIOSYSTEMS GROUP

850 LINCOLN CENTRE DRIVE

(Street)

FOSTER CITY

94404

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
APPLERA CORP [ ABI/CRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Senior Vice President

3. Date of Earliest Transaction (Month/Day/Year)
08/02/2004

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Celera Genomics Group Common Stock	08/02/2004		M		18,000	A	$2.8557	154,136.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		240⁽²⁾	D	$11.8	153,896.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		60⁽²⁾	D	$11.73	153,836.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		120⁽²⁾	D	$11.72	153,716.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		60⁽²⁾	D	$11.71	153,656.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		60⁽²⁾	D	$11.68	153,596.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		540⁽²⁾	D	$11.66	153,056.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		420⁽²⁾	D	$11.64	152,636.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		180⁽²⁾	D	$11.62	152,456.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		120⁽²⁾	D	$11.61	152,336.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		60⁽²⁾	D	$11.56	152,276.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		180⁽²⁾	D	$11.55	152,096.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		144⁽²⁾	D	$11.54	151,952.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		60⁽²⁾	D	$11.51	151,892.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		120⁽²⁾	D	$11.5	151,772.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		336⁽²⁾	D	$11.49	151,436.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		204⁽²⁾	D	$11.48	151,232.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		336⁽²⁾	D	$11.47	150,896.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		120⁽²⁾	D	$11.46	150,776.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		120⁽²⁾	D	$11.45	150,656.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		420⁽²⁾	D	$11.44	150,236.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		120⁽²⁾	D	$11.43	150,116.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		540⁽²⁾	D	$11.42	149,576.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		120⁽²⁾	D	$11.41	149,456.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		180⁽²⁾	D	$11.4	149,276.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		60⁽²⁾	D	$11.39	149,216.0325⁽¹⁾	D
Celera Genomics Group Common Stock	08/02/2004		S		60⁽²⁾	D	$11.38	149,156.0325⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Celera Genomics Group Employee Stock Options-Right to Buy	$2.8557	08/02/2004		M			18,000	⁽³⁾	09/15/2004	Celera Genomics Group Common Stock	18,000	$2.8557	0	D

Explanation of Responses:

1. Includes 896.4486 shares of Celera Genomics Group Common Stock purchased between March and June 2004 under the Company's employee stock purchase plan.

2. Reflects transactions executed by an independent third-party administrator pursuant to a 10b5-1 trading program.

3. The options became exercisable in three equal installments on September 15, 1995, 1996, and 1997.

Remarks:

1 of 4 of Forms 4 filed on August 4, 2004 by Michael W. Hunkapiller

	Thomas P. Livingston, Attorney-in-Fact for Michael W. Hunkapiller	08/04/2004
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.